Introduction {#S0001}
============

Fibromyalgia is a worldwide chronic disease that is most common in adult females \[[@CIT0001]\]. The prevalence of fibromyalgia in the United States (US) general population is about 2% \[[@CIT0002]\] and in the UK is 2.8% \[[@CIT0003]\]. Patients who suffer from fibromyalgia in Iran are estimated to constitute around 1.3% to 4% of the general population \[[@CIT0004], [@CIT0005]\]. Widespread pain for more than 3 months and tenderness in some selected tender points are the main signs of fibromyalgia based on criteria of the American College of Rheumatology 1990 for diagnosis of fibromyalgia \[[@CIT0006]\].

Some medications have been used to manage fibromyalgia in Iran and other countries including pain control medication, antidepressants \[[@CIT0007]\], and nutritional supplements \[[@CIT0008]\], none of which is approved for this indication. Pregabalin is the first medicine that was approved by the US Food and Drug Administration (FDA) in 2007 for fibromyalgia \[[@CIT0009]\]. Currently duloxetine and milnacipran are also approved by the FDA for fibromyalgia \[[@CIT0010], [@CIT0011]\]. The first one is available in Iran but in a very negligible volume and the second one is not available in the market because it has not been included in the Iranian Drug List (IDL).

The evidence indicates the considerable economic burden (2298 Canadian dollars only for direct medical costs) of fibromyalgia \[[@CIT0012]\] both on patients and society \[[@CIT0013]\], which has to be attended by policy makers in providing more cost-effective medicines and treatment strategy for the population. One of the important roles of government to implement the Iran national drug policy is to provide equal access for patients to essential drugs \[[@CIT0014]--[@CIT0016]\]. To put into operation this idea, affordability of medicines and balanced utilization of medicines should be achieved \[[@CIT0017]\].

Pregabalin has recently become available in the Iranian market in both domestic generic and imported brand (Lyrica) forms. The price of pregabalin according to the Iranian drug basket could be considered high and is not currently covered by insurance. However, the results of economic evaluation for pregabalin in diabetic peripheral neuropathy in Iran showed that this drug is cost-effective in doses of 300 mg/day or 600 mg/day and they have been recommended to be added to the insurance coverage list \[[@CIT0018]\] but cost-effectiveness of this drug for fibromyalgia has not been evaluated yet. Economic evaluation of medicines is a tool to assess national drug policy criteria such as accessibility and equity \[[@CIT0015], [@CIT0019]\].

Regarding the above statements, we aimed to analyze the cost-effectiveness of pregabalin in the treatment of fibromyalgia in comparison to other alternative treatments in Iran.

Material and methods {#S0002}
====================

Data sources {#S20003}
------------

To evaluate the efficacy of pregabalin in comparison to other alternatives, a systematic review of published studies was conducted. To cover all documents, databases of PubMed, Scopus, Google Scholar, and Cochrane were systematically searched using the keywords "fibromyalgia and pregabalin" and "fibromyalgia" from 1965 to 30 January of 2012. Published English language randomized controlled trial (RCT) studies which had pregabalin as one of their arms were included. Review articles, economic evaluation studies, studies on animals and observational studies were excluded. Full details of inclusion and exclusion criteria are presented in [Table I](#T0001){ref-type="table"}. To evaluate cost of treatment with pregabalin, only the direct medical cost was considered in analysis, upon a clinical expert\'s opinion. Given that there are no considerable laboratory monitoring and diagnostic tests or other supplementary treatment strategy, we only considered the cost of medicines in the analysis. The treatment\'s cost was calculated based on the treatment period of included studies. The medical cost for both brand and generic products available in the Iranian market was calculated for every dose and each study. To calculate the cost of generic medicine we considered the cheapest combination of available dosage forms in Iran and for the brand ones we considered the most expensive combination. The exchange rate at the time declared by Iran\'s central bank was used to exchange Iranian rials (IRR) to US dollars (USD).

###### 

Details of criteria in study selection

  Inclusion criteria                                                                                   Exclusion criteria
  ---------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Published papers in English languageOne arm of pregabalinControlled studiesSubject of fibromyalgia   Unpublished studiesProceedingsBiochemical, pharmacokinetic and non-clinical studiesAnimal studiesPhase 1 and 2 clinical trials without pregabalin armUncontrolled studiesObservational studiesReview studiesEconomic evaluation studies

Study selection {#S20004}
---------------

The title and abstracts of search results were reviewed separately by two authors to eliminate duplicate studies, unrelated subjects and other exclusion criteria. Then the selected articles were double checked before inclusion in the study. In the next step, the full texts of selected studies were scrutinized and reviewed, which led to exclusion of some more studies.

Quality assessment of included studies {#S20005}
--------------------------------------

The methodological quality of each included study was assessed by the Jadad score, which gives every study a score between 0 and 5 based on descriptions of double-blindness, randomization and withdrawals \[[@CIT0020]\]. Based on this method, studies with scores ≥ 3 were considered as high quality and studies with scores ≤ 2 were considered as low quality. In this study, a score less than 3 was considered as an exclusion criterion.

Effects {#S20006}
-------

The outcome of interest for evaluation of efficacy was "pain score reduction from baseline". The pain score was calculated from an 11-point scale (0 = no pain, 10 = worse possible pain) which was declared by the patients themselves for the last 24 h. Some RCTs reported another outcome, "percentage of patients with at least 50% reduction in pain", which was included in our analysis as well.

Incremental cost-effectiveness ratio {#S20007}
------------------------------------

Using the difference of cost and the difference in efficacy, the incremental cost-effectiveness ratio (ICER) for both brand and generic pregabalin in all treatment doses was calculated and parametric sensitivity analysis was performed using the confidence interval of efficacy in each study. The ICERs in this study were considered as the cost (USD) per one more score reduction in mean pain score in comparison to placebo or the cost (USD) needed to achieve one patient with more than 50% pain reduction. The ICERs were compared with both one and three times the gross domestic product (GDP) per capita upon recommendation of WHO-CHOICE \[[@CIT0021]\] to evaluate whether the treatment of fibromyalgia with different evaluated doses is highly cost-effective (when the ICER was less than GDP per capita), cost-effective (when the ICER was between one and three times GDP per capita, or not cost-effective (when the ICER was more than three times GDP per capita), given that there is no accurate cost-effectiveness threshold (willingness to pay) calculated for health care technologies in Iran. The GDP per capita based on the latest statistics released (2010) was 5608 USD \[[@CIT0022]\]. It is notable that the Iranian pharmaco- and health economists estimate the threshold for Iran to be approximately two times the threshold (10 000 USD).

Results {#S0008}
=======

Out of 4012 articles from the searched databases, 3660 articles were from Google Scholar, 169 articles were from PubMed, and the rest were from Scopus. After reviewing the title and abstract, 6 articles were included in the study, and from these articles, two were excluded after reviewing the full text because they were not RCTs ([Figure 1](#F0001){ref-type="fig"}). Finally, 4 RCTs were included in our analysis \[[@CIT0023]--[@CIT0026]\]. For all included articles, the Jadad score was calculated, which is illustrated in [Table II](#T0002){ref-type="table"}. The patients in these included studies were men and women more than 18 years old who had met American College of Rheumatology criteria for fibromyalgia diagnosis and had a pain score of at least 40 mm of 100 mm on the pain visual analogue scale at screening and randomization. The characteristics of included articles are extracted and summarized in [Table III](#T0003){ref-type="table"}. All selected articles were RCTs evaluating the efficacy of pregabalin in comparison to placebo and patients were randomly assigned to one of these groups in a double-blinded condition. The time period of treatment in the selected studies was 8--14 weeks and the dose of treatment was 300--600 mg/day. There was no report comparing pregabalin and other approved treatment for fibromyalgia. Because of diversity in reporting pain control outcomes, the pooling of results for efficacy was not possible; thus the extracted efficacy results regarding the treatment dose were presented separately.

![Flow of process in the selection of studies regarding the efficacy of pregabalin in fibromyalgia](AMS-9-21936-g001){#F0001}

###### 

Jadad score to evaluate the quality of included studies

  Author, year \[reference\]               Randomization   Double-blind   Withdrawal and dropout   Total score
  ---------------------------------------- --------------- -------------- ------------------------ -------------
  Crofford *et al*., 2005 \[[@CIT0025]\]   2               1              1                        4
  Arnold *et al*., 2008 \[[@CIT0024]\]     2               2              1                        5
  Mease *et al*., 2008 \[[@CIT0023]\]      1               1              1                        3
  Paure *et al*., 2011 \[[@CIT0026]\]      1               1              1                        3

###### 

Summarized characteristics of included studies

  Author, year \[reference\]               No. of patients   Age, mean ± SD \[years\]   Dosage        Concurrent therapy                    Duration of study                                                                                                                                                                                 
  ---------------------------------------- ----------------- -------------------------- ------------- ------------------------------------- ---------------------------------------- ----------------------------------- -------------------------------------------------- ----------------------------------------------------------------- ----------
  Crofford *et al*., 2005 \[[@CIT0025]\]   45                484                        Placebo       Preg 150                              Preg 300                                 Preg 450                            150, 300 and 450 mg/day three times daily dosing   Prohibited except for acetaminophen, aspirin and anti-migraines   8 weeks
  49.7 ±10.7                               48.0 ±10.4        47.7 ±10.1                 48.9 ±11.3                                                                                                                                                                                                                                            
  Arnold *et al*., 2008 \[[@CIT0024]\]     41                704                        50.1 ±11.4    300, 450 and 600 mg/day twice daily   Prohibited                               12 weeks                                                                                                                                                 
  Mease *et al*., 2008 \[[@CIT0023]\]      42                706                        Placebo       Preg                                  300 and 450 and 600 mg/day twice daily   Prohibited (except acetaminophen)   12 weeks                                                                                                             
  48.6 ±11.3                               48.8                                                                                                                                                                                                                                                                                               
  Paure *et al*., 2011 \[[@CIT0026]\]      168               505                        Placebo       Preg 300                              Preg 450                                 Preg 600                            300, 450 and 600 mg/day twice daily                Not reported                                                      14 weeks
  48.1 (11.3)                              48.4 (10.8)       48.0 (11.3)                49.6 (11.3)                                                                                                                                                                                                                                           

Preg -- pregabalin

Pregabalin 150 mg/day {#S20009}
---------------------

There was only one study evaluating pregabalin 150 mg/day \[[@CIT0025]\], which reported no significant efficacy for this dose in comparison to placebo. Thus the ICER for this dose was not calculated and this dose was considered as a dominated strategy (less or similar effectiveness but more cost).

Pregabalin 300 mg/day {#S20010}
---------------------

Concerning pregabalin 300 mg/day, out of 4 studies, 2 of them reported no significant efficacy in comparison to placebo \[[@CIT0025], [@CIT0026]\] in terms of pain score reduction. On the basis of two others \[[@CIT0019], [@CIT0020]\], the range of ICER for generic and brand pregabalin 300 mg/day in treatment of fibromyalgia was 30--117 and 309--1203, respectively ([Table IV](#T0004){ref-type="table"}). This indicated that both generic and brand pregabalin 300 mg/ day could be considered as highly cost-effective treatment for fibromyalgia in Iran because their ICERs are less than GDP per capita. Also, one study that reported the efficacy of pregabalin according to the outcome of percentage of patients with more than 50% pain reduction \[[@CIT0023]\] found that the ICER for generic and brand pregabalin 300 mg/day was 428 and 4368, respectively ([Table V](#T0005){ref-type="table"}). This means that both doses are highly cost-effective.

###### 

Summarized results for the studies with difference in mean pain score as outcome

  Pregabalin                  Difference in mean Δ*E* (95% CI)     Cost of treatment (range -- USD)   ICER (range)   The consideration based on comparison of ICER with threshold         
  --------------------------- ------------------------------------ ---------------------------------- -------------- -------------------------------------------------------------- ----- -----
  150 mg/day \[[@CIT0025]\]   [\*](#TF0001){ref-type="table-fn"}   (14--116)                          NA             NA                                                             NA    NA
  300 mg/day \[[@CIT0024]\]   --0.71 (--1.13, --0.29)              (34--349)                          48 (30--117)   491 (309--1203)                                                HCE   HCE
  300 mg/day \[[@CIT0025]\]   [\*](#TF0001){ref-type="table-fn"}   (23--233)                          NA             NA                                                             NA    NA
  300 mg/day \[[@CIT0023]\]   --0.43                               (34--349)                          79             812                                                            HCE   HCE
  300 mg/day \[[@CIT0026]\]   [\*](#TF0001){ref-type="table-fn"}   (34--349)                          NA             NA                                                             NA    NA
  450 mg/day \[[@CIT0024]\]   --0.98 (--1.40, --0.57)              (62--550)                          63 (44--109)   561 (393--965)                                                 HCE   HCE
  450 mg/day \[[@CIT0025]\]   --0.93                               (41--367)                          44             395                                                            HCE   HCE
  450 mg/day \[[@CIT0023]\]   --0.47                               (62--550)                          132            1170                                                           HCE   HCE
  450 mg/day \[[@CIT0026]\]   --0.56                               (62--550)                          111            982                                                            HCE   HCE
  600 mg/day \[[@CIT0025]\]   --1.00 (--1.41, --0.59)              (68--480)                          68 (48--115)   480 (340--814)                                                 HCE   HCE
  600 mg/day \[[@CIT0023]\]   --0.66                               (68--480)                          103            727                                                            HCE   HCE
  600 mg/day \[[@CIT0026]\]   [\*](#TF0001){ref-type="table-fn"}   (68--480)                          NA             NA                                                             NA    NA

Non-significant results (95% CI), NA -- not applicable, HCE -- highly cost-effective

###### 

Summarized results for the studies with percentage of patients with more than 50% pain reduction as outcome

  Pregabalin                  Difference in number of patients with 50% pain Reduction(from 100 Patients) Δ*E*   Cost of treatment in 100 patients(range -- USD)   ICER   The consideration based oncomparison of ICER with threshold         
  --------------------------- ---------------------------------------------------------------------------------- ------------------------------------------------- ------ ------------------------------------------------------------- ----- -----
  300 mg/day \[[@CIT0023]\]   8                                                                                  (3426--34943)                                     428    4368                                                          HCE   HCE
  450 mg/day \[[@CIT0023]\]   8                                                                                  (6166--55029)                                     771    6879                                                          HCE   CE
  600 mg/day \[[@CIT0023]\]   9                                                                                  (6851--47961)                                     761    5329                                                          HCE   HCE

CE -- cost-effective, HCE -- highly cost-effective

Pregabalin 450 mg/day {#S20011}
---------------------

Concerning pregabalin 450 mg/day, the calculated ICER for generic and brand pregabalin was in the range of 44--132 and 393--1170, respectively \[[@CIT0023]--[@CIT0026]\]. It showed that pregabalin 450 mg/day in both generic and brand forms could be considered as highly cost-effective treatment compared with placebo ([Table IV](#T0004){ref-type="table"}). Also there was one study that reported the efficacy of pregabalin 450 mg/day according to the outcome of percentage of patients with more than 50% pain reduction \[[@CIT0019]\] which resulted in the ICER of 771 and 6879 for its generic and brand forms, respectively ([Table V](#T0005){ref-type="table"}). This means that pregabalin 450 mg/day in generic form is "highly cost-effective" but its brand form is "cost-effective".

Pregabalin 600 mg/day {#S20012}
---------------------

Our analysis of pregabalin 600 mg/day showed that except one study that reported no significant efficacy \[[@CIT0026]\], the range of ICER for generic and brand pregabalin 600 mg/day based on the other two studies \[[@CIT0023], [@CIT0024]\] is 48--115 and 340--814, respectively ([Table IV](#T0004){ref-type="table"}). Also there was one study that reported the efficacy of pregabalin 600 mg/day according to the outcome of percentage of patients with more than 50% pain reduction \[[@CIT0023]\]. The ICER for generic and brand forms of this medicine based on this study was 761 and 5329, respectively ([Table V](#T0005){ref-type="table"}). Considering these results from included studies, pregabalin 600 mg/day could be considered as highly cost-effective treatment for managing fibro-myalgia in comparison to placebo.

Discussion {#S0013}
==========

According to our analysis and based on available published evidence, pregabalin 150 mg/day is not a cost-effective treatment because of non-significant efficacy in comparison to placebo. However, the available evidence for this dose was not sufficient to make an appropriate decision. Concerning pregabalin 300 mg/day, there were some variations in the results of selected studies in terms of efficacy and cost-efficacy. Three out of 5 studies indicated that pregabalin in this treatment dose is highly cost-effective, but in 2 studies no significant efficacy was found. Making a decision about this dose would depend on the view of policymakers and existence of further evidence. Pregabalin 450 mg/ day according to the results of 3 out of 4 studies was highly cost-effective either with generic or brand forms. In addition, in one study, it was highly cost-effective in the generic form and cost-effective in the brand form. Pregabalin 600 mg/day in both generic and brand forms was highly cost-effective for fibromyalgia regardless of one study which showed no significant efficacy for this dose.

It is notable that this is the first cost-efficacy analysis in the context of Iran concerning use of pregabalin in fibromyalgia. Given that pregabalin is the only approved medicine for management of fibromyalgia and its availability in Iran in both generic and brand forms, this analysis can be useful for policymakers and also healthcare providers to make appropriate evidence-based decisions in their areas of activity.

Fibromyalgia is a disease which severely affects patients' quality of life, especially in women \[[@CIT0027]\]. A study comparing quality of life in women with fibromyalgia with some other pain-related illnesses such as osteoarthritis, rheumatoid arthritis, permanent osteotomies, chronic obstructive pulmonary disease, and insulin-dependent diabetes showed that the quality of life in patients with fibromyalgia is among the lowest in all attributes \[[@CIT0028]\]. Another study indicated that patients with fibromyalgia suffer from difficulties in personal relationships, jobs and mental health \[[@CIT0029]\], and experience anxiety \[[@CIT0030]\]. A cost-effectiveness analysis in the context of the UK \[[@CIT0031]\] using Markov modeling for 1 year to evaluate pregabalin in the treatment of fibromyalgia showed that the cost per quality-adjusted life year (QALY) gained for using pregabalin compared to placebo was £23,166 and £22,533 for doses of 300 mg/day and 450 mg/day, respectively. They concluded that pregabalin is a cost-effective treatment. In another study in the US \[[@CIT0032]\], a cost-effectiveness analysis was conducted to compare different fibromyalgia management strategies by a decision-analytic model and indirect effectiveness comparison. The results indicated that pregabalin is cost-saving and more effective than placebo, duloxetine, tramadol, milnacipran, and gabapentin.

In our study, we did not use any decision tree or Markov model for economic evaluation of pregabalin in the treatment of fibromyalgia. In estimation of costs related to this treatment, only direct medical costs were taken into account and direct non-medical or indirect costs were excluded. Including these items, we can claim that pregabalin is a more cost-effective treatment.

Considering the present results, pregabalin 450 mg/day and 600 mg/day are recommended to be included in clinical practice guidelines and reimbursement schemes, given that there is no other FDA approved alternative available in the Iranian market. More accurate decisions about pregabalin 300 mg/day need further evidence. Although pregabalin was cost-effective in both generic and brand forms, considering the bioequivalent efficacy of brand and generic forms, including pregabalin in the reimbursement positive list in the generic form would be more rational and cost-saving. Also more direct evidence regarding comparison of pregabalin and other approved medicines including duloxetine and milnacipran is needed to make the decision in a more efficient way.

In conclusion, based on the published available evidence and cost of pregabalin in Iran, pregabalin 450 mg/day and 600 mg/day can be recommended as a cost-effective treatment for fibromyalgia and can be included in clinical practice guidelines and insurance positive lists of Iran. The decision about pregabalin 300 mg/day is dependent on the viewpoint of policymakers and future evidence. A final point is that more evidence on comparison of pregabalin and other approved or off-label alternatives in head-to-head trials is needed to make a more efficient, convincing decision.
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